Physician profile
Michael Kushner
NPI 1750300539
$15,125.48
in general payments reported to CMS, 2019-2025
39 companies · $2,918 in 2025
The $2,918 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $1,468 · 2021: $1,936 · 2022: $2,297 · 2023: $2,203 · 2024: $3,069 · 2025: $2,918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,128 · Education: $60.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,127.97 |
| Education | $60.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,810.60 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,414.27 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,006.14 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $719.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $655.40 | 2023-2025 | Tezspire, Farxiga, Airsupra |
| Celgene Corporation | $522.34 | 2021-2024 | Zeposia |
| Novo Nordisk INC | $445.63 | 2020-2025 | Ozempic, Wegovy |
| Madrigal Pharmaceuticals | $406.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $379.23 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $362.14 | 2020-2023 | |
| Ardelyx, INC. | $334.91 | 2022-2025 | Ibsrela |
| Janssen Scientific Affairs, LLC | $328.69 | 2022-2023 | Xarelto |
| Genzyme Corporation | $319.94 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $309.61 | 2019-2024 | Rebyota, Clenpiq |
| Aimmune Therapeutics, INC. | $293.23 | 2024-2025 | Zenpep |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $259.79 | 2023-2024 | Xarelto |
| Alfasigma USA, INC. | $230.83 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $229.96 | 2019-2024 | Linzess |
| Braintree Laboratories, INC. | $227.40 | 2019-2023 | Suflave, Sutab |
| Phathom Pharmaceuticals, INC. | $219.28 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $218.05 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $215.72 | 2020-2023 | Dificid |
| Redhill Biopharma INC. | $179.31 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.81 | 2023-2024 | Jardiance, Cyltezo |
| Janssen Biotech, INC. | $147.71 | 2024-2025 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $132.93 | 2024 | |
| Lilly USA, LLC | $111.78 | 2022-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $99.76 | 2025 | Dupixent |
| Qol Medical, LLC | $85.58 | 2022-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $80.89 | 2020-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.74 | 2022-2024 | |
| Amgen INC. | $35.68 | 2023 | Amjevita, Avsola |
| Endo Pharmaceuticals INC. | $30.21 | 2020 | |
| Daiichi Sankyo INC. | $27.72 | 2023 | Injectafer |
| Astellas Pharma US INC | $22.59 | 2025 | Veozah |
| Capsovision, INC. | $21.24 | 2024 | Capsocam Plus |
| Celltrion USA INC. | $16.79 | 2024 | Vegzelma |
| Romark Laboratories, Lc | $16.39 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $2.30 | 2023 | Blueboost |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kushner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.